Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities

Cash Flow Statement

Daily Values

Growth Metrics

Arcadia Biosciences (RKDA) Goodwill (2020 - 2021)

Arcadia Biosciences filings provide 2 years of Goodwill readings, the most recent being $1.2 million for Q4 2021.

On a quarterly basis, Goodwill rose 203.92% to $1.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.2 million, a 203.92% increase, with the full-year FY2021 number at $1.2 million, up 203.92% from a year prior.
Goodwill hit $1.2 million in Q4 2021 for Arcadia Biosciences, down from $1.6 million in the prior quarter.
In the past five years, Goodwill ranged from a high of $1.6 million in Q2 2021 to a low of $301000.0 in Q3 2020.